2-(7-Bromothieno[2,3-g]indazol-1-yl)ethanamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 2-(7-Bromothieno[2,3-g]indazol-1-yl)ethanamine
• 化学式: C₁₁H₁₀BrN₃S
• 分子量: 296.19
• InChiKey: RLCAJCLSXONDFQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  72.1
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• TRICYCLIC PYRROLE OR PYRAZOLE DERIVATIVES
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0990650A1

  公开（公告）日：2000-04-05

  A tricyclic pyrrole or pyrazole derivative represented by the following general formula (I), or a pharmaceutically acceptable salt thereof, which shows strong affinity and selectivity for the 5-HT2C receptor and is useful for the treatment of central nervous system diseases such as sexual disorders, eating disorders, anxiety, depression and sleeping disorders. (In the above formula, each symbol means as follows; Y ring: an unsaturated five-membered ring which may have 1 to 3 of one or more types of hetero atom(s) each selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom or an unsaturated six-membered ring having 1 or 2 nitrogen atom(s), X: a bond or a carbon atom, : a double bond or a single bond, V: a nitrogen atom or a group represented by a formula CH, and A: a straight or branched lower alkylene group which may be substituted with a halogen atom or a cycloalkyl group.)

  一种由以下通式（I）代表的三环吡咯或吡唑衍生物，或其药学上可接受的盐，该衍生物对 5-HT2C 受体具有很强的亲和力和选择性，可用于治疗中枢神经系统疾病，如性障碍、进食障碍、焦虑、抑郁和睡眠障碍。 (在上式中，各符号含义如下； Y 环：不饱和五元环，可具有 1 至 3 个各选自氮原子、氧原子和硫原子的一种或多种杂原子，或具有 1 或 2 个氮原子的不饱和六元环、 X：键或碳原子、 X：键或碳原子，双键或单键、 V：氮原子或由式 CH 代表的基团，以及 A：可被卤素原子或环烷基取代的直链或支链低级亚烷基）。
• Treatment of incontinence with 5htc2 agonists
  申请人：Pfizer Inc.

  公开号：EP2277513A2

  公开（公告）日：2011-01-26

  The present invention relates to the use of agonists of 5-HT2C receptors for the treatment of stress urinary incontinence. The present invention also relates to a method of treatment of stress urinary incontinence, to assays to screen for compounds useful in the treatment of stress urinary incontinence, and to methods of preparing compositions for the treatment of stress urinary incontinence.

  本发明涉及使用5-HT2C受体激动剂治疗压力性尿失禁。本发明还涉及一种治疗压力性尿失禁的方法，涉及筛选用于治疗压力性尿失禁的化合物的检测方法，以及涉及制备治疗压力性尿失禁的组合物的方法。
• Treatment of incontinence
  申请人：Pfizer Inc

  公开号：US20040235856A1

  公开（公告）日：2004-11-25

  The present invention relates to the use of agonists of 5-HT2C receptors for the treatment of urinary incontinence, preferably mixed incontinence or stress urinary incontinence. The invention also relates to the use of antagonists of 5-HT2C receptors for the treatment of urine retention. The present invention also relates to a method of treatment of incontinence, to assays to screen for compounds useful in the treatment of incontinence, and to methods of preparing compositions for the treatment of urinary incontinence.

  本发明涉及使用 5-HT2C 受体的激动剂治疗尿失禁，最好是混合性尿失禁或压力性尿失禁。本发明还涉及使用 5-HT2C 受体拮抗剂治疗尿潴留。本发明还涉及一种治疗尿失禁的方法，涉及筛选治疗尿失禁有用化合物的检测方法，以及制备治疗尿失禁组合物的方法。
• TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS
  申请人：Pfizer Limited

  公开号：EP1620081A2

  公开（公告）日：2006-02-01
• Treatment of Incontinence
  申请人：McMurray Gordon

  公开号：US20080146583A1

  公开（公告）日：2008-06-19

  The present invention relates to the use of agonists of 5-HT2C receptors for the treatment of urinary incontinence, preferably mixed incontinence or stress urinary incontinence. The invention also relates to the use of antagonists of 5-HT2C receptors for the treatment of urine retention. The present invention also relates to a method of treatment of incontinence, to assays to screen for compounds useful in the treatment of incontinence, and to methods of preparing compositions for the treatment of urinary incontinence.